Boryung Pharma And Fellow Korean Firms Sign A Handful Of Overseas Deals – Bio Korea 2013
This article was originally published in PharmAsia News
Boryung, Taejoon, Ilyang and other Korean pharma signed agreements to bring their products to the Middle East, Mongolia and Japan.
You may also be interested in...
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.